Revelation Biosciences, Inc.
REVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.
Other share classesREVBW
13F holders, Q4 2025
Institutional positions in Revelation Biosciences, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- +4 vs. Q3 2025
- Shares held
- 1.23M
- +850.9K (+223.9%) vs. Q3 2025
- Total value
- $984.3K
- +$444.6K (+82.4%) vs. Q3 2025
- New holders
- 8
- 4 more added
- Sold out
- 4
- 0 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting REVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 12 | $313.2K |
| Q1 2026 | 12 | $599.8K |
| Q4 2025 | 14 | $984.3K |
| Q3 2025 | 10 | $539.7K |
| Q2 2025 | 8 | $64.2K |
| Q1 2025 | 7 | $13.3K |
| Q4 2024 | 10 | $49.4K |
| Q3 2024 | 7 | $84.3K |
| Q2 2024 | 7 | $95.8K |
| Q1 2024 | 7 | $20.9K |
| Q4 2023 | 10 | $467.3K |
| Q3 2023 | 11 | $656.3K |
| Q2 2023 | 10 | $758.7K |
| Q1 2023 | 11 | $1.05M |
| Q4 2022 | 10 | $426.9K |
| Q3 2022 | 14 | $588.6K |
| Q2 2022 | 12 | $3.57M |
| Q1 2022 | 16 | $3.44M |
| Q4 2021 | 2 | $657.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Revelation Biosciences, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 605,702 | $484.4K | 4.04% | +398,651+192.5% | Added |
| Armistice Capital, LLC | 434,272 | $347.3K | 0.01% | +354,272+442.8% | Added |
| Citadel Advisors LLC | 54,728 | $43.8K | 0.00% | +54,728 | New |
| Vanguard Group Inc | 52,505 | $42.0K | 0.00% | +52,505 | New |
| Geode Capital Management, LLC | 34,019 | $27.2K | 0.00% | +34,019 | New |
| Northern Trust Corp | 21,907 | $17.5K | 0.00% | +21,907 | New |
| HRT Financial LP | 15,320 | $12.0K | 0.00% | +15,320 | New |
| XTX Topco Ltd | 11,319 | $9.05K | 0.00% | +11,319 | New |
| UBS Group AG | 724 | $579 | 0.00% | +722+36,100.0% | Added |
| SBI Securities Co., Ltd. | 458 | $366 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 47 | $38 | 0.00% | +33+235.7% | Added |
| Danske Bank A/S | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 2 | $0 | 0.00% | +2 | New |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 38 | $0 | 0.00% | +38 | New |
| DRW Securities, LLC | 0 | $0 | 0.00% | −77,272−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −14,764−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −534−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |